How Smart Investors Look at Apellis Pharmaceuticals (APLS).

Now trading at a price of $65.14, Apellis Pharmaceuticals has moved -2.32% so far today. In contrast, the S&P 500 index moved 0.57%.

Apellis Pharmaceuticals shares moved 56.81% over the last 52 weeks, with a high of $70.75 and a low of $33.32. During this time, the stock outperformed the S&P 500 index by 66.04%. As of January 2022, the company's 50-day average price is $53.0. Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The mid-cap Basic Materials company is based in Waltham, MA.

Declining EPS Growth Trend but Improving Debt Levels:

2019-12-31 2020-12-31 2021-12-31 2022-12-31
Revenue (k) n/a $250,646 $66,563 $75,422
Revenue Growth n/a n/a -73.44% 13.31%
Gross Margins n/a 44.38% -165.57% -267.48%
Gross Margins Growth n/a n/a -473.07% -61.55%
Operating Margins n/a -85.27% -805.67% -788.38%
Operating Margins Growth n/a n/a -844.85% 2.15%
Earnings Per Share -$4.77 -$4.53 -$7.65 -$5.89
EPS Growth n/a 5.03% -68.87% 23.01%
Free Cash Flow (k) -$212,828 -$165,910 -$564,229 -$515,269
FCF Growth n/a 22.05% -240.08% 8.68%
Capital Expenditures (k) $1,693 $5,422 $1,103 $1,524
LT Debt to Equity 4.17 1.75 0.95 0.55

Apellis Pharmaceuticals has negative earnings for the current period, so its trailing twelve month P/E ratio is not meaningful. Its forward P/E isn't meaningful either because its guidance EPS is -3.29.

Apellis Pharmaceuticals's P/B ratio is 17.67 compared to its sector average of 2.08. The company is likely overvalued in terms of its book value.

Apellis Pharmaceuticals Trades Below Its Target Price:

15 analysts are following Apellis Pharmaceuticals and have set target prices ranging from $51.0 to $139.0 per share. On average, they have given the company a rating of buy. At the current price of $65.14, APLS is trading -24.14% away from its average analyst target price of $85.87 per share, implying an analyst consensus of strong upside potential for the stock.

The company has no information on the number of shares sold short since 0.11% of the company's shares are tied to short positions. Institutions own 92% of Apellis Pharmaceuticals's shares, while the insider ownership rate stands at 15%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.